- Home
- ACRV vs ASRT Comparison
ACRV vs ASRT Comparison
Compare ACRV & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRV | ASRT |
|---|---|---|
| Founded | 2018 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.5M | 75.1M |
| IPO Year | 2022 | 1997 |
Fundamental Metrics
Financial Performance| Metric | ACRV | ASRT |
|---|---|---|
| Price | $2.46 | $9.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $14.67 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 431.3K | 53.3K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $805.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 9.22 |
| 52 Week Low | $1.05 | $7.71 |
| 52 Week High | $8.00 | $15.15 |
Technical Indicators
Market Signals| Indicator | ACRV | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 89.36 |
| Support Level | $2.12 | $8.61 |
| Resistance Level | $2.59 | $10.42 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | -0.00 | 0.99 |
| Stochastic Oscillator | 59.17 | 89.19 |
Price Performance
Historical ComparisonAbout ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.